Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. increased its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 95.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,905 shares of the company’s stock after purchasing an additional 25,851 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Recursion Pharmaceuticals were worth $349,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter valued at approximately $25,000. GAMMA Investing LLC raised its holdings in Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the last quarter. Amalgamated Bank raised its holdings in Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the last quarter. San Luis Wealth Advisors LLC purchased a new stake in Recursion Pharmaceuticals during the third quarter worth $69,000. Finally, Vontobel Holding Ltd. purchased a new position in shares of Recursion Pharmaceuticals in the third quarter valued at $70,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on RXRX. Jefferies Financial Group decreased their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Needham & Company LLC cut their price objective on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Finally, KeyCorp reduced their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $9.40.

Insider Activity

In related news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $6.82, for a total value of $78,068.54. Following the sale, the director now directly owns 7,144,216 shares of the company’s stock, valued at approximately $48,723,553.12. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $6.82, for a total value of $78,068.54. Following the transaction, the director now owns 7,144,216 shares in the company, valued at $48,723,553.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total value of $37,860.00. Following the sale, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,288,380.78. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 201,682 shares of company stock valued at $1,322,013 in the last 90 days. 15.75% of the stock is currently owned by insiders.

Recursion Pharmaceuticals Stock Down 0.9 %

Shares of NASDAQ RXRX opened at $6.68 on Thursday. The firm has a market cap of $1.88 billion, a P/E ratio of -4.12 and a beta of 0.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.97 and a 1 year high of $15.74. The firm’s 50 day moving average price is $6.68 and its 200 day moving average price is $7.66.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. During the same period in the prior year, the firm earned ($0.38) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 30.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.